|
1. Balakumar P, Singh H, Singh M, Anand-Srivastava MB. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res. 2009 Jul; 60(1): 18-23. doi:10.1016/j.phrs.2009.03.002 2. Lesnefsky EJ, Chen Q, Tandler B, Hoppel CL. Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies. Annu Rev Pharmacol Toxicol. 2017 Jan; 57: 535-65. doi:10.1146/annurev-pharmtox-010715-103335 3. Grace PA. Ischaemia-reperfusion injury. Br J Surg. 1994 May; 81(5): 637-47. 4. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, et al. Role of sarcolemmal K ATP channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest. 2002 Feb; 109(4): 509-16. doi:10.1172/JCI14270 5. Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S, et al. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther. 2006 Feb; 316(2): 670-78. doi:10.1124/jpet.105.092023 6. Rousou AJ, Ericsson M, Federman M, Levitsky S, McCully JD. Opening of mitochondrial KATP channels enhances cardioprotection through the modulation of mitochondrial matrix volume, calcium accumulation, and respiration. Am J Physiol Heart Circ Physiol. 2004 Nov; 287(5): H1967-76. 7. Taliyan R, Singh M, Sharma PL, Yadav HN, Sidhu KS. Possible involvement of 1-adrenergic receptor and KATP channels in cardioprotective effect of remote aortic preconditioning in isolated rat heart. J Cardiovasc Dis Res. 2010 Jul-Sep; 1(3): 145-51. doi:10.4103/0975-3583.70917 8. Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Paizis IA, Steimberg N, et al. Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid. 2002 Apr; 12(4): 325-29. 9. Uchiyama Y, Otani H, Wakeno M, Okada T, Uchiyama T, Sumida T, et al. Role of mitochondrial KATP channels and protein kinase C in ischaemic preconditioning. Clinical and experimental pharmacology and physiology. 2003 May; 30(5-6): 426-36. doi:10.1046/j.1440-1681.2003.03853.x 10. Oziol L, Faure P, Vergely C, Rochette L, Artur Y, Chomard P, et al. In vitro free radical scavenging capacity of thyroid hormones and structural analogues. J Endocrinol. 2001 Jul; 170(1): 197-206. 11. Sayre NL, Sifuentes M, Holstein D, Cheng SY, Zhu X, Lechleiter JD. Stimulation of astrocyte fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage. J Cereb Blood Flow Metab. 2017 Feb; 37(2):514-27. doi:10.1177/0271678X16629153 12. Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Tzeis SM, Carageorgiou HC, et al. Long-term thyroxine administration increases heat stress protein-70 mRNA expression and attenuates p38 MAP kinase activity in response to ischaemia. J Endocrinol. 2001 Jul; 170(1): 207-15. 13. Marais E, Genade S, Huisamen B, Strijdom J, Moolman J, Lochner A. Activation of 938 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol. 2001; 33(4): 769-78. 14. McCord JM. Human disease, free radicals, and the oxidant/antioxidant balance. Clin Biochem. 1993 Oct; 26(5): 351-57. 15. Katoh H, Nishigaki N, Hayashi H. Diazoxide opens the mitochondrial permeability transition pore and alters Ca2+ transients in rat ventricular myocytes. Circulation. 2002 Jun; 105(22): 2666-71. 16. Liang Y, Kongstad O, Luo J, Liao Q, Holm M, Olsson B, Yuan S. QT dispersion failed to estimate the global dispersion of ventricular repolarization measured using monophasic action potential mapping technique in swine and patients. J Electrocardiol. 2005 Jan; 38(1): 19-27. doi:10.1016/j.jelectrocard.2004.09.012 17. Eckle T, Grenz T, Köhler D, Redel A, Falk M, Rolauffs B, et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5): H2533-H2540. doi:10.1152/ajpheart.00472.2006 18. Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammadghasemi F, Khori V. Role of endogenous oxytocin in cardiac ischemic preconditioning. Regul Pept. 2011 Feb; 167(1): 86-90. doi:10.1016/j.regpep.2010.11.004 19. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem. 1966 Aug; 16(2): 359-64. 20. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res. 2001 Nov; 52(2): 181-98. 21. Lin HY, Glinsky GV, Mousa SA, Davis PJ. Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget. 2015 Jun; 6(17): 14735-43. 22. Pantos C, Mourouzis I, Saranteas T, Clavé G, Ligeret H, Noack-Fraissignes P, et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009 Jan; 104(1): 69-77. doi:10.1007/s00395-008-0758-4 23. Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther. 2010 Jun; 24(3): 225-34. doi:10.1007/s10557-010-6236-x 24. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol. 2010 Mar; 105(2): 151-54. doi:10.1007/s00395-009-0080-9 25. Zhang X, Xiao Z, Yao J, Zhao G, Fa X, Niu J. Participation of protein kinase C in the activation of Nrf2 signaling by ischemic preconditioning in the isolated rabbit heart. Mol Cell Biochem. 2013 Jan; 372(1-2): 169-79. doi:10.1007/s11010-012-1458-9 26. Costa AD, Garlid KD. Intramitochondrial signaling: interactions among mitoKATP, PKCε, ROS, and MPT. Am J Physiol Heart Circ Physiol. 2008; 295(2): H874-H882. doi:10.1152/ajpheart.01189.2007 27. Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem. 2007; 20(1-4): 1-22. doi:10.1159/000103747 28. Niemann CU, Saeed M, Akbari H, Jacobsen W, Benet LZ, Christians U, et al. Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther. 2002 Sep; 302(3): 1123-8. 29. Kumar A, Taliyan R, Sharma PL. Evaluation of thyroid hormone induced pharmacological preconditioning on cardiomyocyte protection against ischemic-reperfusion injury. Indian J Pharmacol. 2012 Jan; 44(1): 68-72. doi:10.4103/0253-7613.91870 30. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013 Aug; 169(8): 1672-92. doi:10.1111/bph.12131 31. Kanwal A, Nizami HL, Mallapudi S, Putcha UK, Mohan GK, Banerjee SK. Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury. Biochem Biophys Res Commun. 2016 Apr; 472(2): 392-98. doi:10.1016/j.bbrc.2016.02.016 32. Pantos C, Malliopoulou V, Mourouzis I, Thempeyioti A, Paizis I, Dimopoulos A, et al. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res. 2006 May; 38(5): 308-13. doi:10.1055/s-2006-925404
|
